Zura Bio Limited (NASDAQ:ZURA) Receives Consensus Rating of "Buy" from Analysts

Shares of Zura Bio Limited (NASDAQ:ZURA - Get Free Report) have earned a consensus rating of "Buy" from the eight ratings firms that are covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $14.67.

Several equities research analysts recently commented on the stock. HC Wainwright reissued a "buy" rating on shares of Zura Bio in a report on Thursday, April 3rd. Guggenheim reiterated a "buy" rating and issued a $15.00 price objective on shares of Zura Bio in a report on Wednesday, March 26th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zura Bio in a research report on Wednesday, December 11th. Chardan Capital cut their price objective on Zura Bio from $12.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, March 26th. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $19.00 target price (down previously from $20.00) on shares of Zura Bio in a research report on Wednesday, March 26th.

Zura Bio Trading Up 3.0 %

Shares of Zura Bio stock traded up $0.04 during trading hours on Friday, reaching $1.19. The stock had a trading volume of 73,858 shares, compared to its average volume of 382,481. Zura Bio has a twelve month low of $0.97 and a twelve month high of $6.35. The firm has a market capitalization of $81.02 million, a PE ratio of -2.24 and a beta of 0.08. The stock's 50 day moving average is $1.39 and its 200 day moving average is $2.61.

Zura Bio (NASDAQ:ZURA - Get Free Report) last released its quarterly earnings results on Tuesday, March 25th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.09. The business had revenue of $0.00 million during the quarter. As a group, sell-side analysts predict that Zura Bio will post -0.65 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC lifted its holdings in Zura Bio by 51.6% during the 4th quarter. SG Americas Securities LLC now owns 23,005 shares of the company's stock worth $58,000 after buying an additional 7,828 shares in the last quarter. Wells Fargo & Company MN raised its stake in shares of Zura Bio by 68.6% in the fourth quarter. Wells Fargo & Company MN now owns 23,053 shares of the company's stock valued at $58,000 after acquiring an additional 9,379 shares in the last quarter. Bank of America Corp DE boosted its holdings in Zura Bio by 31.9% in the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company's stock valued at $103,000 after purchasing an additional 9,966 shares during the period. Rhumbline Advisers grew its stake in Zura Bio by 37.3% during the 4th quarter. Rhumbline Advisers now owns 37,657 shares of the company's stock worth $94,000 after purchasing an additional 10,231 shares in the last quarter. Finally, American Century Companies Inc. purchased a new stake in Zura Bio during the 4th quarter worth about $27,000. Hedge funds and other institutional investors own 61.14% of the company's stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.